DOI: 10.1001/jamanetworkopen.2026.36432 ISSN: 2574-3805
Pembrolizumab vs Nivolumab as Initial Treatment for Advanced, Unresectable, or Metastatic Melanoma
Garth W. Strohbehn, Josiah D. Nieto, Daniel A. Goldstein, Alex K. BryantThis comparative effectiveness research study examines outcomes associated with pembrolizumab and nivolumab among US veterans with advanced, unresectable, or metastatic melanoma.